AHA Scientific Sessions 2026 Abstract · Nov 2, 2026
CHIR99021 Loaded Thermogel Enhances the Therapeutic Potential of Human Induced Pluripotent Stem Cell-Derived Cardiomyocytes After Myocardial Infarction
By Zheng Z, Li X, Tang W et al.
Background: Human induced pluripotent stem cell-derived cardiomyocytes (hiPSC-CMs) represent a promising regenerative therapy for myocardial infarction (MI), but poor graft retention and limited proliferative capacity remain major translational barriers. CHIR99021, a selective GSK3 inhibitor, can promote cardiomyocyte cell-cycle activity; however, its short local retention limits its therapeutic utility. We developed an injectable CHIR99021-loaded nanoparticle thermogel system to enhance hiPSC-CM-based cardiac repair after MI. Methods: CHIR99021 was encapsulated into PLGA nanoparticles and incorporated into PLGA-PEG-PLGA thermosensitive hydrogel (NP CHIR @Gel). In vitro, hiPSC-CMs were treated with CHIR99021, and cell-cycle activity was assessed by EdU incorporation, Aurora B immunostaining, and Western blotting at 0, 6, 12, 24, and 48 hours. In vivo, MI was induced in NOD-SCID mice, followed by intramyocardial injection of hiPSC-CMs (1х105 cells/site, 3х105 cells/animal) with and without NP CHIR @Gel. Therapeutic potential was evaluated by echocardiography, human cardiac troponin T immunostaining, and Sirius Red/Fast Green staining four weeks post operation. Results: CHIR99021 markedly enhanced hiPSC-CM cell-cycle activity, as shown by increased EdU incorporation and Aurora B midbody-like signals. Time-course Western blotting demonstrated progressive activation of cell-cycle regulators, including phospho-Rb, Cyclin D2, Cyclin B1, and phospho-histone H3, together with downregulation of p27 (Panel A). In vivo, human cardiac troponin T staining showed around 10 times greater graft retention in the hiPSC-CM+NP CHIR @Gel treated mice compared to the hiPSC-CMs treated alone (Panel B). Echocardiography demonstrated improved left ventricular ejection fraction after combined treatment compared with MI and hiPSC-CM treated groups (Panel C). Sirius Red/Fast Green staining further showed reduced infarct scar formation in hiPSC-CM+NP CHIR @Gel treated mice compared with hiPSC-CMs and MI treated animals (Panel D). Conclusion: Local delivery of NP CHIR @Gel enhances hiPSC-CM therapeutic potential after MI by promoting cardiomyocyte cell-cycle activity, improving graft retention, reducing infarct scarring, and restoring cardiac function. This biomaterial-assisted strategy may provide a practical approach to improve the efficacy of hiPSC-CM-based myocardial regeneration.